Oncology biomarkers market to grow to $33.63B by 2030, driven by personalized cancer therapies and AI advances

The global oncology biomarkers market is projected to grow from $19.73 billion in 2026 to $33.63 billion by 2030, with a CAGR of 14.3%. Growth is fueled by rising cancer incidence, expansion of screening programs, advances in molecular biology, AI-driven biomarker discovery, and adoption of liquid biopsy technologies. Key players like F Hoffmann-La Roche AG and Novartis AG are innovating in biomarker-based cancer diagnostics to improve early detection and personalized treatment. The market is also supported by collaborations between research institutions and hospitals, with North America leading in market share.